By
Drug Target Review2025-10-03T09:21:07
Researchers have developed a new blood test method, CloneSeq-SV, that tracks treatment-resistant ovarian cancer cells over time. The approach could help predict recurrence and guide targeted therapies.
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2025-10-08T14:00:00
Sponsored by Eurofins Discovery
2025-11-13T14:00:00
Sponsored by Cell Signaling Technology
2025-05-08T10:38:52
Sponsored by Takara Bio USA
2023-05-31T15:16:10
Sponsored by Bio-Techne
2024-05-07T13:11:19
Sponsored by BellBrook Labs
2026-05-22T07:38:00
Contributor Dr Helen Bright, By Drug Target Review
Site powered by Webvision Cloud